Arvinas logo
Close this search box.

Research and Development

Arvinas scientific staff preparing materials for testing

Working to Bring New Medicines to Patients to Address Immediate Unmet Needs

Arvinas is dedicated to advancing comprehensive programs in oncology and neurodegeneration, including against targets that have traditionally been deemed “undruggable.”

Arvinas scientific staff preparing materials for testing
Image of protein test vial
Arvinas scientific staffer looking into microscope

We Create PROteolysis Targeting Chimeras

We are engineering an expansive pipeline of proteolysis targeting chimeras, or PROTAC® protein degraders, designed to harness the body’s own natural protein disposal system (the ubiquitin proteasome system) to selectively and efficiently degrade and remove disease-causing proteins.

Our Research

Arvinas is currently the only targeted protein degradation company with investigational drugs nearing pivotal trials.

Arvinas scientific staff member preparing vials for testing

Breast Cancer

Vepdegestrant (ARV-471) is an estrogen receptor targeting PROTAC® protein degrader currently being investigated for the potential treatment of patients with locally advanced or metastatic estrogen receptor (ER) positive / human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer 

Arvinas scientific staffer reviewing brain scans on monitor


We are pioneering the discovery of PROTAC® protein degraders in neurologic diseases, which have historically been difficult to treat


Learn more about our pipeline and clinical programs

The agents listed above are currently under investigation. Their safety and effectiveness have not yet been established.

Smiling Arvinas scientific staff member talking with colleague
Arvinas scientific staff

If you’re inspired, please take a look at the current list of opportunities to join our team.


You are now leaving Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

Skip to content